A total of 381 RA patients were treated with low-dose IL-2, including new RA patients (66.39% female patients, mean age 56.16 ± 13.24 years), treated RA patients (68.21% female patients, mean age 55.37 ± 13.14 years), and D2T RA patients (66.67% female patients, mean age 56.83 ± 13.28 years). The gene discussed is IL2; the disease is rheumatoid arthritis.